. Crystal structure of the LeuO-EBD dimer. One EBD monomer of the LeuO-EBD dimer is shown in gray ribbon (left), with amino acids Leu122, Tyr168, Phe219, and M243 lining the pocket of the EBD's cleft depicted as sticks. The second EBD monomer is shown in tubes in green, blue, yellow, and orange. Residues that render LeuO inactive when replaced by aspartic and glutamic acid, respectively, are indicated as magenta spheres (Pro121, Leu122, Ile125, Tyr168, and Leu263, right monomer). Residues Met243 and Phe219 (depicted as grey sticks, left monomer) when replaced by glutamic acid do not affect LeuO-activity. The numbering of residues is according to the full-length protein sequence of LeuO. The figure was prepared using Chimera (1) . Figure S2 . Characterization of additional LeuO mutants. Regulation of Pcas-lacZ by additional LeuO mutants was determined in strain T1281. Expression levels were determined of cultures grown without induction (top panel) or with 1 mM IPTG for induction of leuO expression (bottom panel). (Left) PcaslacZ expression was analyzed of transformants carrying pKESK22-derived plasmids (p15A origin of replication) for Ptac-directed expression of wild-type LeuO (pKETS5), S120D (pKESL104), S120A (pKESL108), R218C (pKESL78), R218A (pKESL238), R218E (pKESL243), M244T (pKESL73), M244A (pKESMS1), S120D/M244T (pKESL107), C117S (pKESMS64), C117D (pKESMS67), C119S (pKESMS65), and C119D (pKESMS66); empty vector pKESK22 served as a control (vector). (Right) Pcas-lacZ expression was analyzed in transformants carrying low copy plasmids (pSC origin of replication) with the lacUV5 promoter (P UV5 ) directing expression of wild-type LeuO (pKESL39), S120D (pKESL102), P121D (pKESL69), L122E (pKESL103), I125E (pKESL64), Y168E (pKESL70), F219E (pKESL67), M243E (pKESL61), and L263E (pKESL62). The empty parent vector of these plasmids served as control (vector). Cultures for β-galactosidase assays were inoculated from overnight cultures and grown in LB medium with appropriate antibiotics to an OD 600 of 0.5. Mean values of at least 3 independent biological replicates are shown as bars; error bars indicate standard deviations. Figure S3 . DNase I footprinting of the cas promoter region with LeuO His6 , LeuO-DBD His6 , and LeuO-S120D His6 . Autoradiograms of (A) fragment 'c' (top strand) and (B) fragment 'd' (bottom strand) covering LeuO DNA-binding site I ( figure 4A ). The labeled DNA fragments were incubated with increasing protein concentrations of LeuO His6 , LeuO-DBD His6 and LeuO-S120D His6 , as indicated. Samples were separated on 6% denaturing polyacrylamide gels. Open arrowheads indicate hypersensitive sites. The sequence of the protected DNA region is marked with solid lines and given to the right with the sequence of the DNA-binding core-site in bold; dotted lines indicate additional protections. 
Figure S7
Autoregulation of leuO by LeuO mutants. Autoregulation of leuO was analyzed using a chromosomal PleuO-lacZ reporter present in strains T862 (bglJ C ), and T352 (Δhns stpA) ( Table 1) . Transformants of these strains with the vector control (pKESK22), and plasmids providing LeuO (pKETS5), hyperactive LeuO mutants (Table S1) , and LeuO-DBD (pKESMS63) were grown in LB kanamycin medium to an OD 600 of 0.5 without induction (top) or with induction by adition 1 mM IPTG (bottom). Mean values of at least 3 independent biological replicates are shown as bars, and error bars indicate standard deviations. Pcas lacZ in pKES268 Pcas cloned with T736/T737 pKESL39
leuO-S120D-EBD-His6 in pET-22b(+) constructed for protein purification pKESMS16
leuO-His6 in pET-22b(+) constructed for protein purification pKESMS17
leuO-S120D-His6 in pET-22b(+) constructed for protein purification pKESMS21
leuO-EBD-His6 in pET-22b(+) constructed for protein purification
leuO-DBD-His6 in pET-22b(+) constructed for protein purification a) The following abbreviations and genetic designations are used: MCS, multiple cloning site, rep ts , temperature sensitive origin of replication, aadA refers to spectinomycin resistance, cmR for chloramphenicol resistance, kanR for kanamycin resistance, ampR for ampicillin resistance. DBD refers to the N-terminal DNA-binding domain of LeuO, from amino acid 1 to amino acid 101 of the protein. EBD refers to the C-terminal effector-binding domain of LeuO, from amino acid 108 to amino acid 314 (end of protein). b) For cloning, PCR fragments were amplified with the oligonucleotides listed in table S2. Vectors and PCR fragments were digested with restriction enzymes, gel purified and cloned. All plasmids were analyzed by PCR, restriction digestion, and sequencing of the cloned fragment. Screen: LeuO mutant screen using either Pcas-lacZ (T1281, T1610) or Pbgl-lacZ (T568) as reporter, LeuO mutants marked with (2x) and (3x) were isolated two or three times independently (from independent PCR runs), the asterisk (*) marks mutations that were isolated independently but with different secondary mutation or synonymous substitution. 2 a For motif generation using MEME-Suite (10) 33 base sequences were compiled in FASTA files. b Given is the genome coordinate of the center of the 33 bp sequences. c Motifs 1 and 2 are depicted in Figure 5 top and bottom, respectively. Figure 5 to FIMO. The search identified 37 putative LeuO DNA-binding sites shown here. e) Loci were identified in a microarray (MA) transcriptome analysis and the given values refer to the fold change regulation (4). f) Loci were identified by genome scale SELEX (SL) screening and the given values refer to the peak height (12) . g) Descriptions of gene functions shown in bold are taken from the EcoCyc Database (13) .
